Introduction
Merkel cell carcinoma (MCC) was first described by Toker Reference Toker1 in 1972 as a trabecular carcinoma of the skin. It is a rare, highly aggressive neuroendocrine malignancy that most commonly affects the skin. MCC most commonly occurs on the head and neck (50%) and extremities (40%), with the remainder occurring on the trunk. Reference Vesely, Murray and Neligan2 It predominantly affects older adults with fair skin and has a propensity for local recurrence and regional lymph node metastases, resulting in a 5-year survival rate of around 60%. Reference Tothill, Estall and Rischin3,Reference Schrama, Ugurel and Becker4 The annual incidence of MCC has risen from 0·5 cases per 100,000 cases in 2000 (95% CI: 0·4–0·5) to 0·7 cases per 100,000 cases in 2013 (95% CI: 0·7–0·8). Reference Paulson, Park and Vandeven5 Despite the aggressive nature of this malignancy, there have been reports of spontaneous regression. We report the first case of primary complete spontaneous regression (CSR) of MCC involving the anterior mediastinum and lacking cutaneous involvement.
Clinical History
We report on the treatment of a 50-year-old male patient who presented with a 3-month history of a mobile mass in his low anterior neck, near the sternal notch. Diagnostic CT confirmed a hypo-enhancing soft tissue mass in the upper anterior mediastinum at the level of the sternoclavicular joint, measuring 2·6 cm, without overlying skin changes. Ultrasound-guided FNA (Fine Needle Aspiration) biopsy was positive for MCC, CK20 (Cytokeratin 20) with dot-like perinuclear positive, synaptophysin positive, TTF (thyroid transcription factor)-1 negative and chromogranin negative. A few weeks later, PET/CT confirmed a hypermetabolic paratracheal mass measuring approximately 3·1 cm with no other signs of FDG-avid disease. When the patient was seen in our ENT department approximately 1 month later, he reported that over a couple of months since the biopsy, the mass had gradually disappeared. On physical exam, there were no visible abnormalities or palpable masses within the neck or mediastinum. A CT scan of the chest for metastatic workup, which included the entire mediastinum and the low neck, was negative for the disease. Figure 1 displays a CT scan prior to and after the biopsy.
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20220428144328981-0505:S1460396920000862:S1460396920000862_fig1.png?pub-status=live)
Figure 1. CT scan of mediastinal mass before biopsy (left) and after biopsy (right).
The case was discussed at the Head and Neck tumour board, with a decision to recommend radiation to the area where the tumour had been for microscopic tumour control. CT done at the time of radiation simulation was negative for the disease. He was then treated with intensity modulated radiation therapy to a dose of 6,160 cGy in 28 fractions to the site where the tumour was visible on previous imaging. At-risk nodes (levels III–VI) were also treated to 5,000 cGy in 28 fractions. Treatment duration was for a total of 43 calendar days. Treatment was well tolerated. The patient experienced odynophagia not requiring medication and dry desquamation at the treatment field requiring Silvadene.
He was seen for follow-up at 3 and 6 months following completion of radiation therapy with resolution of acute toxicities at the 3-month mark. The exam was performed at both follow-up appointments with no evidence of the disease. PET/CT 3 months after the completion of radiation therapy showed no new/residual sites of FDG avidity. This study is approved by a broad-based Institutional Review Board dosimetric study.
Discussion
Several case reports have been published regarding spontaneous regression of MCC following incisional biopsy. This is the first case at our institution to have spontaneous regression both seen on physical exam and imaging for an anterior mediastinal lesion, with no evidence of skin involvement.
CSR of an MCC is rare and predicted to be 1·5–3% but may be greater than reported. Reference Ciudad, Aviles, Alfageme, Lecona, Suarez and Lazaro6,Reference Sais, Admella and Soler7 While most cases of primary CSR were originally located on the cheek, no report has shown CSR of a biopsy-proven anterior mediastinal MCC. The mechanism of spontaneous regression is not clearly understood. Evidence suggests increased immune activity around the tumour regression site in the form of tumour-infiltrating lymphocytes may play a role. Reference Walsh8 Several studies reported heavy infiltration of CD4+, CD8+, CD3+ T-lymphocytes and foamy macrophages around the tumour nest. As in most previously reported cases, CSR in our case occurred following a biopsy, which suggests a potential stimulation of the immune system. Reference Takenaka, Kishimoto and Shibagaki9
Baker utilised TCR (T-cell receptor) sequencing to demonstrate that spontaneous regression of an MCC is driven by the expansion of novel and pre-existing adaptive cellular immune responses. Similar results were seen with immunohistochemical staining and TCR sequencing performed in an MCC tumour regressing during the treatment with the PD-L1 (programmed death-ligand 1) inhibitor, avelumab. Reference Baker, Roman and Reuben10
Conclusion
In summary, this is an isolated case report of spontaneous regression of an MCC in the anterior mediastinum with no cutaneous involvement. Most cases of MCC with reported spontaneous regression are in the head/neck region with evidence of cutaneous involvement.
Acknowledgements
None.